The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MGNX | -47.67% | -91.09% | -38.35% | -93% |
| S&P | +15.06% | +95.03% | +14.29% | +298% |
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
The company announced second-quarter earnings.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $22.24M | 106.0% |
| Gross Profit | $11.43M | 85.4% |
| Gross Margin | 51.38% | -5.7% |
| Market Cap | $76.34M | -71.3% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 341 | 0.6% |
| Net Income | -$36.25M | 34.9% |
| EBITDA | -$34.85M | 38.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $130.69M | 55.7% |
| Accounts Receivable | $12.53M | 102.4% |
| Inventory | 9.3 | 731.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $102.39M | 245.3% |
| Short Term Debt | $5.12M | 16.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -16.30% | 37.5% |
| Return On Invested Capital | -47.52% | 2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$47.70M | -4.8% |
| Operating Free Cash Flow | -$46.99M | -5.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.57 | 1.70 | 0.69 | 0.96 | -61.48% |
| Price to Sales | 1.46 | 1.36 | 0.52 | 0.46 | -92.89% |
| Price to Tangible Book Value | 3.57 | 1.70 | 0.69 | 0.96 | -61.48% |
| Enterprise Value to EBITDA | 0.72 | -0.77 | 0.90 | -0.21 | -92.50% |
| Return on Equity | -62.2% | -49.9% | -60.2% | -69.7% | -41.38% |
| Total Debt | $34.10M | $37.46M | $37.47M | $107.51M | 215.67% |
MGNX earnings call for the period ending December 31, 2024.
MGNX earnings call for the period ending September 30, 2024.
MGNX earnings call for the period ending March 31, 2024.
MGNX earnings call for the period ending December 31, 2023.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
